Circumvention of atypical multidrug resistance with tumor necrosis factor

G. Cimoli, M. Valenti, S. Parodi, F. De Sessa, P. Russo

Research output: Contribution to journalArticlepeer-review


Some 'multidrug-resistant' (MDR) cell lines are not associated with a defect in drug accumulation or with the overexpression of P-glycoprotein. These cell lines are defined as 'atypical MDR' (at-MDR) and they often express altered or mutated topoisomerase II. We investigated the ability of tumor necrosis factor to reverse at-MDR (in the human ovarian cancer cell line A2780 DX3) on the basis of its efficacy in potentiating in vitro topoisomerase II-targeted drugs, and because there is convincing evidence that the synergy is due to an increased number of topoisomerase-associated strand-breaks as well as to an increased level of extractable topoisomerase.

Original languageEnglish
Pages (from-to)135-138
Number of pages4
JournalJapanese Journal of Cancer Research
Issue number2
Publication statusPublished - 1994


  • Multidrug resistance (atypical)
  • Ovarian cancer
  • TNF
  • Topoisomerase II

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Circumvention of atypical multidrug resistance with tumor necrosis factor'. Together they form a unique fingerprint.

Cite this